Phase III Study of Efaproxiral As an Adjunct to Whole-Brain Radiation Therapy for Brain Metastases

医学 临床终点 乳腺癌 放射治疗 肺癌 内科学 危险系数 脑转移 比例危险模型 不利影响 肿瘤科 癌症 外科 置信区间 转移 随机对照试验
作者
John H. Suh,Baldassarre Stea,Abdenour Nabid,John J. Kresl,A. Fortin,Jean-Philippe Mercier,Neil N. Senzer,Eric Lin Chang,Adam P. Boyd,Pablo J. Cagnoni,Edward Shaw
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:24 (1): 106-114 被引量:197
标识
DOI:10.1200/jco.2004.00.1768
摘要

PURPOSE: To determine whether efaproxiral, an allosteric modifier of hemoglobin, improves survival in patients with brain metastases when used as an adjunct to whole-brain radiation therapy (WBRT). PATIENTS AND METHODS: Patients with brain metastases from solid tumors and a Karnofsky performance score of > or = 70 were randomly assigned to receive WBRT with supplemental oxygen and either efaproxiral at 75 or 100 mg/kg (efaproxiral arm) or no efaproxiral (control arm). The primary end point was survival. RESULTS: The study consisted of 515 eligible patients (efaproxiral arm, n = 265; control arm, n = 250). The median survival time (MST) was 5.4 months for the efaproxiral arm versus 4.4 months for the control arm (hazard ratio [HR] = 0.87; P = .16). For the subgroup of patients with non-small-cell lung cancer (NSCLC) or breast cancer, the MST was 6.0 and 4.4 months, respectively (HR = 0.82; P = .07). Cox multiple regression analysis demonstrated a significant reduction in the risk of death for the efaproxiral arm in both primary populations. Further analysis indicated that the benefit may be restricted to the subgroup of patients with breast cancer. Response rates (radiographic complete response plus partial response) improved by 7% (P = .10) and 13% (P = .01) for all patients and for NSCLC and breast cancer patients in the efaproxiral arm, respectively. The most common severe adverse event in patients treated with efaproxiral was hypoxemia, which was reversible and effectively managed with supplemental oxygen in most patients. CONCLUSION: The addition of efaproxiral, a noncytotoxic radiation sensitizer, to WBRT may improve response rates and survival in patients with brain metastases, particularly metastases from breast cancer. A confirmatory trial for breast cancer patients has been initiated.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
Ceylon发布了新的文献求助10
1秒前
Echen发布了新的文献求助10
2秒前
PatrickL完成签到,获得积分10
2秒前
科研通AI6.3的应助被单虽然采纳,获得10
2秒前
2秒前
3秒前
超级涵山发布了新的文献求助10
3秒前
古芍昂发布了新的文献求助10
3秒前
可爱的函函的应助被小小迷糊采纳,获得10
4秒前
科研大印完成签到,获得积分10
5秒前
脏脏包发布了新的文献求助10
5秒前
6秒前
6秒前
调皮元珊发布了新的文献求助10
6秒前
李爱国的应助被尊敬的雨竹采纳,获得10
7秒前
和谐的雪瑶完成签到,获得积分20
7秒前
念兹在兹完成签到,获得积分10
7秒前
CarryLJR的应助被NiMing采纳,获得10
8秒前
chen发布了新的文献求助10
8秒前
8秒前
cv发布了新的文献求助10
9秒前
星期日发布了新的文献求助10
9秒前
Echen完成签到,获得积分10
9秒前
10秒前
共享精神的应助被小粒橙采纳,获得10
11秒前
大个的应助被PhD采纳,获得10
12秒前
junge发布了新的文献求助10
12秒前
彭于晏的应助被zzyh采纳,获得10
12秒前
淡定完成签到,获得积分10
13秒前
Adax发布了新的文献求助10
13秒前
生动的芝麻完成签到,获得积分10
13秒前
13秒前
14秒前
科研通AI2S的应助被糊涂的电话采纳,获得10
15秒前
15秒前
淡定发布了新的文献求助30
15秒前
搜集达人的应助被自然的含蕾采纳,获得10
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178695
求助须知:如何正确求助?哪些是违规求助? 9569449
关于积分的说明 21804643
捐赠科研通 7773744
什么是DOI,文献DOI怎么找? 3432903
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478500